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Introduction to the Problem
In 2011 the Center for Disease Control (CDC) declared opioid abuse an epidemic. In
2017 it was declared a public health emergency. The practice of anesthesia and many other
medical specialties have placed a priority on limiting the administration of opioids to help
combat this crisis. In the practice of anesthesia, techniques such as opioid-sparing, opioid-free,
peripheral nerve blocks, and neuraxial blocks have become the preferred choice to limit the
exposure of patients to opioids when it is appropriate.
In labor and delivery, neuraxial anesthesia has been used for over a hundred years to
provide pain relief for parturients. Although many alternatives have been studied, opioids are the
most frequently used local anesthetic adjuvants and their use in neuraxial blocks has evolved
over the last 50 years (Swain et al., 2017). While neuraxial opioids have proven to be an
effective adjunct for pain relief, they are associated with undesirable side effects as well as the
exposure of the patient to the opioid itself. With the push for opioid-free techniques, researchers
searched for non-narcotic alternatives that can provide the same benefits as their narcotic
counterparts. Dexmedetomidine (DEX) is an opioid-free, selective alpha-2 agonist that has been
shown to be equal to, and in most cases, superior to opioid additives in neuraxial blockade (Qi et
al., 2016).

Literature Review

Neuraxial opioids are associated with side effects that can cause a great deal of
discomfort to parturients, and in some cases these side effects can be lethal. While many other
side effects have been described, the four classic side effects are pruritus, nausea and vomiting,
urinary retention, and respiratory depression. DEX is not associated with any of these side
effects. The relatively small side effect profile of neuraxial DEX makes it a desirable nonnarcotic alternative to opioids. The most common adverse reactions associated with neuraxial
DEX are prolonged sensory and motor block, dose-dependent transient hypotension, and
bradycardia.
Multiple studies have produced similar conclusions regarding the use of DEX as an
adjunct to epidural anesthesia. In a meta-analysis conducted by Qian et al. (2020) that included
nine randomized control studies (RCT) and 672 patients, it was concluded that “DEX is better
than fentanyl as an adjuvant to ropivacaine for epidural anesthesia with better effects and less
adverse events.” Another meta-analysis conducted by Li et al. (2021), which included nine
studies and 1403 patients, reached similar conclusions stating: “DEX as an adjuvant to epidural
local anesthetics has the potential to offer a better analgesic effect than placebo, similar labor
pain control to opioids, and has no definite adverse effects on the parturient or fetus.” Compared
to neuraxial opioids, DEX shows a reduction in adverse reactions without the loss of analgesic
effects when used for labor epidurals. Similar results have been reached regarding intrathecal
DEX. A study by Qi et al. (2016) surmised, “Intrathecal DEX supplementation produced
prolonged sensory and motor blockade and similar analgesic effects compared with
supplementation using 100 µg of morphine. Furthermore, intrathecal DEX additive produced

fewer side effects compared with morphine.” Additionally, post-operative time to first
analgesics was longer and total opioid consumption at 24 and 48-hour intervals were lower in the
DEX group.
Neuraxial dosing for DEX as an adjuvant therapy has a somewhat wide range of dosing
guidelines. Intrathecal dosing for DEX in most studies recommends 5 μg. However, a more
recent study by Bi et al. (2020) concluded that: “ 3 µg intrathecal DEX as an adjuvant to
ropivacaine improved intraoperative somato-visceral sensory block characteristics and
postoperative analgesia, alleviated shivering in parturients, and did not prolong the time of motor
block or produce any side effects, which makes this dose appropriate for cesarean delivery.” For
epidural dosing, the consensus of most studies falls in the range of 0.5-1.5 mcg/kg (Yousef et
al. 2015; Zhao et al. 2017; Selim et al. 2012; Soni 2016). Alfandy et al. (2021), states: “The dose
of DEX as an epidural adjuvant ranged between 0.5 μg/kg and 1.5 μg/kg. It is known to cause
dose–dependent bradycardia and hypotension; a relatively low fixed-dose (50 μg) was given to
all the patients as their weights were within a narrow range to avoid exacerbation of maternal
hypotension or bradycardia.”

Methods
The goal of this project was to educate and institute a protocol for the licensed anesthesia
providers in the Obstetric department about the use of neuraxial Dexmedetomidine as an opioidfree replacement for patients during the entire labor process. The sample group was given a pretest to assess their knowledge and experience with neuraxial DEX and initial feelings on
implementing DEX into their practice. Upon completing the pre-test, the group was given a
PowerPoint presentation and all questions were answered satisfactorily. In addition, all

participants were given a copy of the PowerPoint presentation and a “fast Facts” handout with
dosing guidelines and adverse reactions. Approximately two weeks after training, the sample
group was given a post-test to assess knowledge retention and willingness to implement DEX
into their current practice.
The sample group consisted of the 25 licensed anesthesia providers that provide care to
the labor and delivery unit of a 300-bed suburban hospital in Bradenton, Fl. Additionally, four
Nurse Anesthesia Residents were included in the training. All 25 participants completed the pretest, post-test, and training along with the four students. This project was submitted to Southern
Illinois University’s IRB committee for approval and was granted an exemption. The project is a
quality improvement project and does not include human subject experimentation. The research
evaluated for this project is based on randomized studies with no identifiable patient information.
Evaluation
This non-experimental project was aimed to educate anesthesia practitioners on current
practices of using the opioid-free neuraxial adjunct DEX for parturients in labor and delivery.
One hundred percent of the study group, including the four students, indicated that they had no
prior experience using DEX in this manner. The primary knowledge instruments deployed in this
project were a pre-test and a post-test, done approximately two weeks apart. The pre-test
consisted of thirteen questions, of which five were demographic questions, seven were
knowledge-based questions, and one used a Likert scale to determine the likelihood of use of the
adjunct. The post-test consisted of fourteen questions including five demographic, seven
knowledge-based, one Likert scale, and one assessing the teaching aids employed.
The licensed practitioners in the sample group had a mean experience of 17.84 years.
This represents an experienced group of practitioners learning about a new adjunct to their

practice. As expected, the baseline knowledge of dosing and adverse reactions to neuraxial DEX
was low. Overall, the presentation and instruction increased the scores of the study group from
the pre-test to the post-test. Specifically, the licensed providers saw an average of a 73% increase
in their score on the neuraxial dosing questions. The licensed providers also saw a 56% increase
in scores on the questions regarding adverse reactions of neuraxial DEX. The students
experienced an increase of 100% on the neuraxial dosing questions and 75% on the adverse
reaction questions. After presentation and instruction, 32% of licensed providers responded that
they were more likely to incorporate neuraxial DEX into their regular practice in labor and
delivery.
One of the limitations of this project was the small sample size. This sample
group was a sample of convenience. A larger sample size, possibly including different
institutions, could gain a better idea of the effectiveness of the teaching, presentation, and
handouts. Another limitation of this project was the relatively small sample sizes in the studies
that describe the use of DEX as an adjunct to neuraxial anesthesia. Larger, multi-institutional
studies can strengthen current research findings on this topic.

Impact to Practice
With the opioid epidemic still raging, the practice of anesthesia is changing and evolving
to help combat the public health emergency. Many different techniques to limit the use of
opioids are being researched, including opioid-free anesthesia, Enhanced Recovery After
Surgery (ERAS), peripheral nerve blocks, and neuraxial anesthesia. Parturients experience
intense visceral pain during labor. Neuraxial anesthesia is the preferred method of anesthesia for
Cesarian Sections due to the maternal physiologic changes that pregnancy causes. Opioids have

been the chosen adjuncts to neuraxial anesthesia for this population due to their enhanced pain
control during and after delivery. However, this can come with undesirable and potentially lethal
side effects. Neuraxial DEX can eliminate these adverse reactions while providing equal or
superior pain relief during and after labor and delivery.

Sustainability
The information and training aids will be reviewed and update regularly as new studies
and information are made available. The required post-operative order sets will be made
available to the anesthesia providers within the CERNER system for use by all providers. The
pharmacy department will stock the appropriate vials of DEX in the Pyxis for use by the
providers. All employees will have access to the teaching information in the anesthesia office.
Additionally, all new employees will be given the teaching information. This information and
training will be provided to the staff at no cost.

Conclusion/Recommendations
DEX, as an adjunct to neuraxial anesthesia, has the potential to offer anesthesia providers
and patients an opioid-free option for pain control and relief. The presentation, hand-outs, and
instruction given to the anesthesia providers in the sample group were successful in educating
them on the use, dosing, and adverse reactions of this medication. This offered the knowledge
and confidence for successfully implementing this opioid-free option in their practice to improve
the outcomes for their patients.

For some parturients, DEX alone during the labor process could offer pain relief without
loss of sensation in their lower extremities. This could be studied to see if it is a viable option.
Further studies and uses of this medication to extend past labor and delivery could be beneficial.
This could include using the adjunct for lower extremity surgeries that currently use neuraxial
blocks.
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